Abstract

The Pilot and Feasibility Program supports young investigators beginning their careers in CF research, as well as providing the opportunity for more seasoned investigators to explore new avenues of research. Additionally, the program offers an enticement for investigators who may have an expertise of interest to CF, but without support to initiate research in CF. As a recent change to processing pilot and feasibility applications, the institutional CTSA has agreed to add the CF Pilot and Feasibility to its """"""""WebGrants"""""""" system for soliciting and collecting proposals. This system has a greater distribution list to faculty who may have novel ideas for CF, and provides a more uniform process for individuals to apply. Once applications are received, they are forwarded to us for review. Applications are reviewed internally or externally, depending on needed expertise and awarded proposals are funded for up to 2 years each for $65,000. Investigators awarded through this mechanism are expected to participate in the Center's seminar series and to apply for extramural funding as well.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK027651-31
Application #
8638924
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
31
Fiscal Year
2014
Total Cost
Indirect Cost

  Institution

Name
Case Western Reserve University
Department
Type
DUNS #
City
Cleveland
State
OH
Country
United States
Zip Code
44106

  Publications

Lai, Nicola; M Kummitha, China; Rosca, Mariana G et al. (2018) Isolation of mitochondrial subpopulations from skeletal muscle: Optimizing recovery and preserving integrity. Acta Physiol (Oxf) :e13182
Donnola, Shannon B; Dasenbrook, Elliott C; Weaver, David et al. (2017) Preliminary comparison of normalized T1 and non-contrast perfusion MRI assessments of regional lung disease in cystic fibrosis patients. J Cyst Fibros 16:283-290
Darrah, Rebecca; Nelson, Rebecca; Damato, Elizabeth G et al. (2016) Growth Deficiency in Cystic Fibrosis Is Observable at Birth and Predictive of Early Pulmonary Function. Biol Res Nurs 18:498-504
VanDevanter, Donald R; Morris, Nathan J; Konstan, Michael W (2016) IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis. J Cyst Fibros 15:372-9
VanDevanter, D R; Flume, P A; Morris, N et al. (2016) Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis. J Cyst Fibros 15:783-790
Jiang, Kai; Jiao, Sen; Vitko, Megan et al. (2016) The impact of Cystic Fibrosis Transmembrane Regulator Disruption on cardiac function and stress response. J Cyst Fibros 15:34-42
Bruscia, Emanuela M; Bonfield, Tracey L (2016) Cystic Fibrosis Lung Immunity: The Role of the Macrophage. J Innate Immun 8:550-563
Hsu, Daniel; Taylor, Patricia; Fletcher, Dave et al. (2016) Interleukin-17 Pathophysiology and Therapeutic Intervention in Cystic Fibrosis Lung Infection and Inflammation. Infect Immun 84:2410-21
Rymut, Sharon M; Kampman, Claire M; Corey, Deborah A et al. (2016) Ibuprofen regulation of microtubule dynamics in cystic fibrosis epithelial cells. Am J Physiol Lung Cell Mol Physiol 311:L317-27
Than, B L N; Linnekamp, J F; Starr, T K et al. (2016) CFTR is a tumor suppressor gene in murine and human intestinal cancer. Oncogene 35:4179-87

Showing the most recent 10 out of 445 publications